Наша группа организует более 3000 глобальных конференций Ежегодные мероприятия в США, Европе и США. Азия при поддержке еще 1000 научных обществ и публикует более 700 Открытого доступа Журналы, в которых представлены более 50 000 выдающихся деятелей, авторитетных учёных, входящих в редколлегии.
Журналы открытого доступа набирают больше читателей и цитируемости
700 журналов и 15 000 000 читателей Каждый журнал получает более 25 000 читателей
Prakash Krishnan
The current outbreak of COVID‐19 caused by 2019‐nCoV has already taken away plethora of human lives. There is an urgent need for cost effective, available, safe, and effective medicine for fighting this virus. As on date, there is no specific medication available for COVID-19. The bitter taste receptor -TAS2R family (present in human airway smooth muscle) is an important player in host defence mechanisms. Considering the caffeine role as bitter agonists to stimulate the TAS2Rs and to activate host defence mechanisms and to suppress the cytokine storms due to its anti-inflammatory action, caffeine can play as an agent for support therapy in the control of SARS-COV-2. Studies demonstrate that caffeine apart from its role as a central nervous system stimulant has proven the ability as an antiviral agent by its role in inhibiting viral protein synthesis. This article is an approach to attract the attention of caffeine researchers to highlight onto the possibilities and suggest the population with beneficial and accessible remedies.